Recombinant Cynomolgus Monkey VSIG4 Fc Chimera Protein, CF

Recombinant Cynomolgus Monkey VSIG4 Fc Chimera (Catalog #10155-VS) inhibits anti-CD3 antibody induced IFN-gamma secretion by human T cells. The ED50 for this effect is 0.6-6 μg/mL.

2 μg/lane of Recombinant Cynomolgus Monkey VSIG4 Fc Chimera (Catalog # 10155-VS) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie Blue staining, showing bands at 67-76 kDa and 130-150 kDa, respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey VSIG4 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 0.6-6 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey VSIG4 protein
  

  Cynomolgus Monkey VSIG4 (Arg25-Pro288) Accession # XP_005593850.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005593850.1
• N-terminal Sequence: Arg25
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 58 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 67-76 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey VSIG4 Fc Chimera Protein, CF

• CRIg
• Ig superfamily protein
• Protein Z39Ig
• V-set and immunoglobulin domain containing 4
• V-set and immunoglobulin domain-containing protein 4
• VSIG4
• Z39IG
• Z39IGcomplement receptor of the immunoglobulin superfamily

Background

VSIG4 (V-set and immunoglobulin domain containing 4), also known as CRIg and Z39IG, is a 45 kDa, type I transmembrane protein of the B7 family within the Ig superfamily that is expressed only in tissue-resident macrophages (1-4). The cynomolgus VSIG4 cDNA encodes 404 amino acids (aa) including a 24 aa signal sequence, a 264 aa extracellular domain (ECD) containing a V-type and a C2-type Ig domain, a 23 aa transmembrane domain and a 93 aa cytoplasmic domain (5). The cynomolgus VSIG4 ECD shares 94% aa identity with human VSIG4 ECD.  VSIG4 is specifically expressed on macrophages in the thymic medulla, peritoneum, alveoli, synovia, adipose and heart, liver Kupffer cells, placental Hofbauer cells, and atherosclerotic foam cells (1-4, 6-9). It is absent on infiltrating macrophages (8). VSIG4 is a complement receptor that binds C3b and iC3b fragments, internalizes them to recycling endosomes, and is recycled to the cell surface (4, 6). It contributes significantly to innate immunity by binding and phagocytosis of complement-opsonized invading pathogens (4, 8, 10). Binding of either native or recombinant soluble VSIG4 to C3b inhibits complement amplification through the alternative, but not classical, pathway (10, 11). VSIG4 is also a negative regulator of mouse and human T cell activation (2). Although VSIG4 engagement may activate NF kappa B and thus be pro-inflammatory in some cases, many of its activities are important in resolving, rather than initiating, inflammation (1, 2, 7, 10, 11).

1. He, J.Q. et al. (2008) Mol. Immunol. 4041.
2. Vogt, L. et al. (2006) J. Clin. Invest. 116:2817.
3. Langnaese, K. et al. (2000) Biochim. Biophys. Acta 1492:522.
4. Helmy, K. et al. (2006) Cell 124:915.
5. Entrez protein Accession # A0A2K5TW73, XP_005593850.
6. Tanaka, M. et al. (2008) Clin. Exp. Immunol. 154:38.
7. Lee, M-Y. et al. (2006) J. Leukoc. Biol. 80:922.
8. Gorgani, N.N. et al. (2008) J. Immunol. 181:7902.
9. Walker, M.G. (2002) Biochim. Biophys. Acta 1574:387.
10. Wiesmann, C. et al. (2006) Nature 444:217.
11. Katschke, K.J. et al. (2007) J. Exp. Med. 204:1319.

Bioinformatics

• Uniprot:
  • XP_005593850.1()